CING
NASDAQ
$4.78
Cingulate Inc (CING)
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders. The company is headquartered in Kansas City, Kansas.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $23 (+381.68%)
Market Cap
$55M
Free Cash Flow Yield
-36.18%
Beta (5Y)
1.25
Price Chart
Valuation
Market Cap$55M
P/B3.38
Profitability
Gross Profit (TTM)-$9.74M
EBITDA-$24M
EPS-$3.89
Financial Health
Free Cash Flow Yield-36.18%
Growth & Risk
Beta (5Y)1.25
Sharpe Ratio0.35